Latest Insider Transactions at Catalent, Inc. (CTLT)
This section provides a real-time view of insider transactions for Catalent, Inc. (CTLT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Catalent, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Catalent, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 15
2021
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
4,500
-3.1%
|
$495,000
$110.05 P/Share
|
|
Jun 23
2021
|
Ricardo Pravda Chief Transformation Officer |
SELL
Open market or private sale
|
Direct |
2,800
-20.19%
|
$308,000
$110.58 P/Share
|
|
Jun 01
2021
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
BUY
Grant, award, or other acquisition
|
Direct |
3,432
+17.37%
|
-
|
|
Jun 01
2021
|
Thomas P Castellano SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,451
+14.03%
|
-
|
|
May 10
2021
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Bona fide gift
|
Direct |
20
-0.06%
|
-
|
|
Apr 28
2021
|
Michael J Barber Director |
BUY
Grant, award, or other acquisition
|
Direct |
845
+50.0%
|
-
|
|
Mar 22
2021
|
Kay A Schmidt SVP, Enterprise Functions |
SELL
Open market or private sale
|
Direct |
1,400
-9.17%
|
$147,000
$105.77 P/Share
|
|
Mar 19
2021
|
John R Chiminski Executive Chair |
SELL
Open market or private sale
|
Direct |
183,024
-20.43%
|
$19,400,544
$106.32 P/Share
|
|
Mar 19
2021
|
John R Chiminski Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
183,024
+14.38%
|
$7,687,008
$42.44 P/Share
|
|
Mar 18
2021
|
John R Chiminski Executive Chair |
SELL
Open market or private sale
|
Direct |
42,220
-20.51%
|
$4,433,100
$105.16 P/Share
|
|
Mar 18
2021
|
John R Chiminski Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
42,220
+17.02%
|
$1,519,920
$36.02 P/Share
|
|
Mar 18
2021
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
21,647
-12.12%
|
$2,251,288
$104.6 P/Share
|
|
Mar 18
2021
|
Steven L Fasman EVP & Chief Admin Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,647
+10.63%
|
$844,233
$39.95 P/Share
|
|
Feb 16
2021
|
Wetteny Joseph SVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.36%
|
$620,000
$124.92 P/Share
|
|
Feb 16
2021
|
Wetteny Joseph SVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.37%
|
$245,000
$49.41 P/Share
|
|
Feb 08
2021
|
Wetteny Joseph SVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,604
-8.46%
|
$520,252
$113.73 P/Share
|
|
Jan 21
2021
|
Ricci S Whitlow President, CSS |
SELL
Open market or private sale
|
Direct |
692
-21.18%
|
$81,656
$118.85 P/Share
|
|
Jan 11
2021
|
Karen Flynn Director |
SELL
Open market or private sale
|
Direct |
2,478
-3.4%
|
$277,536
$112.32 P/Share
|
|
Jan 06
2021
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
61
-0.37%
|
$6,344
$104.78 P/Share
|
|
Jan 04
2021
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Open market or private sale
|
Direct |
16
-0.04%
|
$1,664
$104.42 P/Share
|
|
Jan 04
2021
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
189
-0.26%
|
$19,656
$104.42 P/Share
|
|
Jan 04
2021
|
Karen Flynn Director |
SELL
Open market or private sale
|
Direct |
99
-0.27%
|
$10,296
$104.42 P/Share
|
|
Jan 04
2021
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
110
-0.21%
|
$11,440
$104.42 P/Share
|
|
Jan 04
2021
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
126
-0.73%
|
$13,104
$104.42 P/Share
|
|
Jan 04
2021
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
120
-0.72%
|
$12,480
$104.42 P/Share
|
|
Jan 04
2021
|
Wetteny Joseph SVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
172
-0.32%
|
$17,888
$104.42 P/Share
|
|
Jan 04
2021
|
Alessandro Maselli President & CEO |
SELL
Open market or private sale
|
Direct |
148
-0.75%
|
$15,392
$104.42 P/Share
|
|
Jan 04
2021
|
Ricardo Pravda Chief Transformation Officer |
SELL
Open market or private sale
|
Direct |
78
-0.56%
|
$8,112
$104.42 P/Share
|
|
Jan 04
2021
|
Kay A Schmidt SVP, Enterprise Functions |
SELL
Open market or private sale
|
Direct |
73
-0.48%
|
$7,592
$104.42 P/Share
|
|
Jan 04
2021
|
Ricci S Whitlow President, CSS |
SELL
Open market or private sale
|
Direct |
83
-2.48%
|
$8,632
$104.42 P/Share
|
|
Dec 21
2020
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
13,662
-11.51%
|
$1,393,524
$102.88 P/Share
|
|
Dec 21
2020
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,662
+10.18%
|
$409,860
$30.23 P/Share
|
|
Dec 17
2020
|
John R Chiminski Executive Chair |
SELL
Bona fide gift
|
Direct |
10,000
-5.76%
|
-
|
|
Nov 23
2020
|
Peter Zippelius Director |
SELL
Open market or private sale
|
Indirect |
5,392,280
-100.0%
|
$533,835,720
$99.26 P/Share
|
|
Nov 23
2020
|
Peter Zippelius Director |
BUY
Conversion of derivative security
|
Indirect |
5,392,280
+50.0%
|
$264,221,720
$49.54 P/Share
|
|
Nov 11
2020
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
2,425
-3.19%
|
$242,500
$100.99 P/Share
|
|
Oct 29
2020
|
Madhavan Balachandran Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+12.48%
|
-
|
|
Oct 29
2020
|
J Martin Carroll Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+10.5%
|
-
|
|
Oct 29
2020
|
John J Greisch Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+15.79%
|
-
|
|
Oct 29
2020
|
Rolf A Classon Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+6.46%
|
-
|
|
Oct 29
2020
|
Christa Kreuzburg Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+19.51%
|
-
|
|
Oct 29
2020
|
Rosemary A Crane Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+15.79%
|
-
|
|
Oct 29
2020
|
Donald E Morel Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+3.86%
|
-
|
|
Oct 29
2020
|
Gregory T Lucier Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+9.73%
|
-
|
|
Oct 29
2020
|
Jack L Stahl Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+6.46%
|
-
|
|
Oct 29
2020
|
Peter Zippelius Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+24.85%
|
-
|
|
Oct 28
2020
|
Ricardo Pravda Chief Transformation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,249
+13.89%
|
-
|
|
Oct 23
2020
|
Kay A Schmidt SVP, Enterprise Functions |
SELL
Payment of exercise price or tax liability
|
Direct |
425
-2.7%
|
$39,950
$94.02 P/Share
|
|
Oct 14
2020
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
5,510
-0.99%
|
$512,430
$93.42 P/Share
|
|
Oct 14
2020
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,515
-5.5%
|
$884,895
$93.15 P/Share
|